Alloy Health, a virtual care platform focused on women in midlife, is expanding its weight care program with two new offerings: micro-dosing options for GLP-1 therapies and access to a daily oral Wegovy pill. The additions are designed to provide more personalized and flexible treatment options, particularly for women who may not tolerate standard dosing or prefer an alternative to injectable medications.
The expanded program builds on Alloy’s menopause-focused care model, which combines physician-led hormonal expertise with metabolic and weight management support. Delivered through an asynchronous, text-based platform, the program integrates GLP-1 therapies with guidance on nutrition, exercise, sleep, and long-term health. Alloy leaders emphasize that weight gain during menopause is often driven by hormonal changes, insulin resistance, and metabolic shifts—factors that have historically been underaddressed in traditional care models.
The introduction of micro-dosing allows clinicians to tailor treatment for patients who need lower or adjusted doses, while the oral GLP-1 option broadens accessibility for those hesitant to use injections. In some cases, Alloy may also offer compounded semaglutide or tirzepatide when clinically appropriate, following regulatory guidance for personalized use. The platform combines medication management with ongoing support, including regular check-ins and individualized care plans.
Alloy positions its program as a holistic approach to midlife health, aiming to treat weight as part of a broader hormonal and metabolic picture rather than a standalone issue. By combining menopause-informed care with modern pharmacological options and lifestyle support, the company seeks to improve outcomes and reduce long-term risks such as cardiovascular disease.
Click here to read the original news story.
